Diagnostic validation of novel Borrelia antigens discovered by whole-proteome microarray: Advancing early detection and test of cure for Lyme disease.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 40315844.
- Also identified by DOI 10.1016/j.xcrm.2025.102097 and PMC identifier 12147846.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Lyme disease serodiagnosis has limited early sensitivity and cannot distinguish active from past infections. To address this, we screen a Borrelia afzelii whole-proteome microarray (1,296 proteins) using human (n = 149) and murine (n = 32) sera. We evaluate three early-stage antigens-BafPKo_A0001, BafPKo_D0016, and BafPKo_A0029. ELISA cutoffs are established using discovery cohort sera (n = 99) and validated with the validation (n = 242) and the prospective (n = 223) cohorts. A0001 demonstrates 87.8% sensitivity, outperforming C6 (69.4%) and STTT (22.5%) in the discovery cohort. In the validation cohort, A0001 reaches 90.5% sensitivity, surpassing C6 by 11.6% and STTT by 50%. In hyper-acute erythema migrans sera (from the prospective cohort), A0001 achieves 55.1% sensitivity, exceeding C6 and STTT by 14.6% and 33.3%, respectively. COMBO-3 and COMBO-2 yield the highest sensitivity of 92.9% and 66.1% in the validation and prospective cohort, respectively. A0001 and D0016 show enhanced and robust seroreversion after antibiotic treatment suggesting their potential as test of cure biomarkers in early Lyme disease.
Medical subject headings
- Lyme Disease
- Antigens, Bacterial
- Proteome
- Protein Array Analysis
- Borrelia